Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

T-RAFIC Training network for tracking and controlling therapeutic immune cells in cancer

Coordinator
Ludwig-Maximilians-Universitaet Muenchen, Germany
Runs
1 March 2025 to 28 February 2029
Status
Running
EU funding
€4.1m
Total cost
—
Partners
28 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101168810

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerating. Currently over 6.000 clinical trials are investigating immune-related treatments in oncology especially in combinations. It includes both adoptive cellular therapies and immune modulating treatments like immune check point blockade. In contrast, the understanding of how such therapies mediate their mode of action is still mostly poorly understood.

In particular, the role of distribution and relocation of immune cells after therapeutic interventions remains unknown. This is surprising, as immune cell interactions are a hallmark of therapeutic immune responses. T-RAFIC will enhance understanding of immune cell trafficking under therapeutic influence. It will open new paths and avenues to treatments, boost their efficacy and help prioritizing the plethora of immune therapeutic combinations.

In the past, detailed analysis of cellular distributions was facing technical barriers. Advances in technologies, now permit tracking and visualization of cells in vitro and in vivo at an unprecedented resolution, allowing for the first time studies on immune cells under therapeutic influence. This emerging field of research has enormous potential and key importance for next generation of researchers in oncology and beyond.

However, experts in this field are missing and this threats European research, development and medicine. Therefore, T-RAFIC joins forces of 19 academic and three industrial partners from nine European countries to conduct an innovative and interdisciplinary approach combining cell imaging with bioinformatics, cell engineering and clinician expertise. The network bundles recognised expertise in cancer immunotherapies, empowering European research and innovation and ensuring a sustainable cooperation in science and training.

Topics

Who is involved

OrganisationCityCountryRole
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyCoordinator
Medizinische Universitat InnsbruckInnsbruckAustriaParticipant
ViraTherapeutics GmbHInnsbruckAustriaAssociatedpartner
Fondazione per L'istituto Di Ricerca in BiomedicinaBellinzonaSwitzerlandAssociatedpartner
InCephalo AGAllschwilSwitzerlandAssociatedpartner
Roche Glycart AGSchlierenSwitzerlandAssociatedpartner
Universita Della Svizzera ItalianaLuganoSwitzerlandAssociatedpartner
Universitat ZurichZurichSwitzerlandAssociatedpartner
Klinikum Der Ludwig-Maximilians-Universitat MunchenMunchenGermanyAssociatedpartner
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyParticipant
Miltenyi Biotec BV & Co KgBergisch GladbachGermanyParticipant
Technische Universitaet MuenchenMuenchenGermanyAssociatedpartner
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Kobenhavns UniversitetKobenhavnDenmarkAssociatedpartner
Region HovedstadenHillerodDenmarkParticipant
Institut Gustave RoussyVillejuifFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite De RennesRennesFranceAssociatedpartner
Universite Paris CiteParisFranceAssociatedpartner
Universite Paris-SaclayGif-Sur-YvetteFranceAssociatedpartner
Universita HumanitasPieve EmanueleItalyParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En PatientenzorgAmsterdamNetherlandsAssociatedpartner
Oslo Universitetssykehus HfOsloNorwayParticipant
Universitetet I OsloOsloNorwayAssociatedpartner
Anglia Ruskin UniversityChelmsfordUnited KingdomAssociatedpartner
Intelligent Omics LimitedNottinghamUnited KingdomAssociatedpartner
The Nottingham Trent UniversityNottinghamUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI